Cellectis Current ratio
Was ist das Current ratio von Cellectis?
Current ratio von Cellectis ist 3.17
Was ist die Definition von Current ratio?
Das derzeitige Verhältnis ist ein Liquiditätsgrad das misst, ob ein Unternehmen über ausreichende Ressourcen verfügt, um seine kurzfristigen Verpflichtungen zu erfüllen.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cellectis
Was macht Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Unternehmen mit current ratio ähnlich Cellectis
- Clean Fuels Corp hat Current ratio von 3.17
- SPS Commerce hat Current ratio von 3.17
- Installux S.A hat Current ratio von 3.17
- NewRiver REIT plc hat Current ratio von 3.17
- Crowd Media hat Current ratio von 3.17
- Pure Cycle hat Current ratio von 3.17
- Cellectis hat Current ratio von 3.17
- AMMO hat Current ratio von 3.17
- AMMO hat Current ratio von 3.17
- Eckert & Ziegler Strahlen- und Medizintechnik AG hat Current ratio von 3.17
- Cadre hat Current ratio von 3.17
- Besunyen hat Current ratio von 3.17
- Youth Champ hat Current ratio von 3.17